An ErbB2 splice variant lacking exon 16 drives lung carcinoma.

Animals Carcinoma / genetics Cell Line, Tumor Female Genetic Predisposition to Disease Humans Lung Neoplasms / genetics Male Mice Protein Isoforms / genetics Rats Receptor, ErbB-2 / genetics Tumor Microenvironment
ErbB2 signaling alternative splicing lung cancer oncogene activation tumor progression

Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
18 08 2020
Historique:
pubmed: 31 7 2020
medline: 7 10 2020
entrez: 31 7 2020
Statut: ppublish

Résumé

Lung cancer causes more deaths annually than any other malignancy. A subset of non-small cell lung cancer (NSCLC) is driven by amplification and overexpression or activating mutation of the receptor tyrosine kinase (RTK)

Identifiants

DOI: 10.1073/pnas.2007474117 PMID: 32727899 PMC: PMC7443881
pubmed: 32727899
pii: 2007474117
doi: 10.1073/pnas.2007474117
pmc: PMC7443881
doi:

Substances chimiques

Protein Isoforms 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20139-20148

Subventions

Organisme : CIHR
ID : FDN-148373
Pays : Canada

Déclaration de conflit d'intérêts

Competing interest statement: E.S.S., D.C.P., G.M.F., and J.C. are current or former employees of Foundation Medicine, the manufacturer of the Comprehensive Genomic Profiling assay used for analysis of clinical samples in this study.

Références

Nat Rev Immunol. 2003 Feb;3(2):133-46
pubmed: 12563297
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Clin Cancer Res. 2018 Jun 1;24(11):2594-2604
pubmed: 29298799
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Cancer Res. 1990 Sep 15;50(18):6075-86
pubmed: 1975513
Nat Cell Biol. 2001 Sep;3(9):785-92
pubmed: 11533657
Cytokine Growth Factor Rev. 2017 Dec;38:10-21
pubmed: 28888485
J Thorac Oncol. 2018 Dec;13(12):1897-1905
pubmed: 30096481
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
RNA Biol. 2015;12(10):1139-51
pubmed: 26367347
J Biol Chem. 2000 Apr 21;275(16):11858-64
pubmed: 10766812
Oncogene. 2016 Nov 24;35(47):6053-6064
pubmed: 27157621
Genes Dev. 2014 Sep 1;28(17):1929-39
pubmed: 25184679
Science. 2010 May 7;328(5979):749-52
pubmed: 20339029
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Cell. 2005 Jun 17;121(6):823-35
pubmed: 15960971
Mol Cancer. 2016 Oct 27;15(1):67
pubmed: 27784305
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Oncologist. 2020 Mar;25(3):e545-e554
pubmed: 32162827
Cancer Cell. 2019 Oct 14;36(4):444-457.e7
pubmed: 31588020
Endocr Relat Cancer. 2006 Mar;13(1):221-32
pubmed: 16601290
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81
pubmed: 22908275
J Thorac Oncol. 2020 Jan;15(1):50-61
pubmed: 31557536
J Thorac Oncol. 2012 Jan;7(1):85-9
pubmed: 22071781
Lancet Oncol. 2011 Feb;12(2):175-80
pubmed: 21277552
J Immunol. 2013 Aug 15;191(4):2009-17
pubmed: 23851682
J Cell Physiol. 2014 Feb;229(2):139-47
pubmed: 23893766
Eur J Cancer. 2019 Mar;109:28-35
pubmed: 30685684
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
JCO Precis Oncol. 2017 Jun;1:
pubmed: 28681041
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Cancer Immunol Immunother. 2015 Sep;64(9):1185-91
pubmed: 26047578
Annu Rev Immunol. 2009;27:485-517
pubmed: 19132915
Cancer Res. 2013 Sep 1;73(17):5320-7
pubmed: 23867476
Trends Genet. 2006 Dec;22(12):649-53
pubmed: 17007958
J Exp Med. 2013 Oct 21;210(11):2435-66
pubmed: 24127486
Nucleic Acids Res. 2006;34(22):e148
pubmed: 17142220
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
In Vitro Cell Dev Biol Anim. 1995 Jul-Aug;31(7):516-27
pubmed: 8528500
Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9
pubmed: 19122144
Cancer Res. 2014 Nov 1;74(21):6248-59
pubmed: 25164009
EMBO J. 1999 Apr 15;18(8):2149-64
pubmed: 10205169
Cancer Cell. 2006 Jun;9(6):485-95
pubmed: 16730237
J Neurooncol. 2016 Oct;130(1):211-219
pubmed: 27531351
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
J Exp Med. 1999 Oct 4;190(7):995-1004
pubmed: 10510089
Nat Rev Mol Cell Biol. 2009 Nov;10(11):741-54
pubmed: 19773805
Genes Dev. 2001 Dec 15;15(24):3249-62
pubmed: 11751631
Am J Respir Cell Mol Biol. 2017 Aug;57(2):248-257
pubmed: 28287822
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3444-9
pubmed: 10716706

Auteurs

Harvey W Smith (HW)

Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; william.muller@mcgill.ca harvey.smith2@mcgill.ca.

Lei Yang (L)

Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.

Chen Ling (C)

Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.

Arlan Walsh (A)

Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.

Victor D Martinez (VD)

Department of Integrative Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada.

Jonathan Boucher (J)

Institute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
ORCID: 0000-0002-4586-3059

Dongmei Zuo (D)

Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.

Ethan S Sokol (ES)

Foundation Medicine, Boston, MA 02141.

Dean C Pavlick (DC)

Foundation Medicine, Boston, MA 02141.

Garrett M Frampton (GM)

Foundation Medicine, Boston, MA 02141.
ORCID: 0000-0002-2361-2750

Juliann Chmielecki (J)

Translational Medicine and Oncology, AstraZeneca, Waltham, MA 02451.

Laura M Jones (LM)

Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.
Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.
Moleculight, Toronto, ON M5G 1T6, Canada.

Philippe P Roux (PP)

Institute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
ORCID: 0000-0002-5962-0250

William W Lockwood (WW)

Department of Integrative Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada.

William J Muller (WJ)

Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; william.muller@mcgill.ca harvey.smith2@mcgill.ca.
Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Isoformes de protéines › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › An ErbB2 splice variant lacking exon 16 drives...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › An ErbB2 splice variant lacking exon 16 drives...